Table 1.
Subject | Age (years) | Sex | Social group | Study year | Illness duration (days)a | Antimicrobials (treatment duration, days) | Fecal transplant |
---|---|---|---|---|---|---|---|
Beatriceb | 1 | F | M | 2013 | 11 | Azithromycin (1), nitazoxanide (3) | No |
Valeria | 1 | F | A | 2015 | 22 | Ampicillin (3), ceftazidime (3), nitazoxanide (10) | Yes |
Gisela | 2 | F | G | 2013 | 15 | Ampicillin (5), ceftazidime (5), ceftiofur (5), metronidazole (5), nitazoxanide (9) | Yes |
Remus | 2 | M | R | 2013 | 20 | Ampicillin (10), ceftazidime (10), metronidazole (6), nitazoxanide (19) | Yes |
Aemilia | 2 | F | D | 2015 | 9 | No | No |
Gertrudec | 3 | F | P | 2016 | > 6 | No | No |
Pontius | 3 | M | D | 2015 | 8 | Metronidazole (5) | No |
Arcadia | 5 | F | D | 2015 | 13 | No | No |
Rupilia | 14 | F | R | 2013 | > 8 | No | No |
Antoniad | 18 | F | A | 2015 | > 3 | Amoxicillin (5), ampicillin (3) | No |
a Values preceded by a greater than symbol (>) are estimates; first day of infection is unknown for these subjects (Gertrude, Rupilia, and Antonia).
b Only pre-infection and recovery samples were available.
c Infection manifested in winter 2016.
d On antimicrobials only during recovery, because they were administered to treat a separate injury, not the infection.